Search bioRxiv⌕ Search

Biology subjects

Wittkowski, H.

Publications and source records attributed to Wittkowski, H..

3 recordsLinked to original sources

Epigenetic control of S100A8/A9-driven monocytic inflammation licenses anti-leukemic functionality of immature NK cells during hematopoietic stem cell differentiation.

Inflammation is a key driver of hematopoietic dysfunction in myeloid malignancies, but its role in the context of hypomethylating therapy remains incompletely understood. Although 5-Azacytidine is used posttransplant in high-risk myelodysplastic syndrome (MDS), only 50% of patients show a clinical response. We provide evidence that inherent inflammatory properties of healthy donor CD34+ stem cells exist that are likely to contribute to the "response" seen in MDS patients. These are linked to epigenetic priming of the myeloid niche, resulting in S100A8/A9-driven inflammatory program that promotes functionality of immature NK cells. Using in vitro differentiation systems, multi-omic profiling, and a S100A9-/- mouse model, we find that 5-AzaC modulates inflammatory transcriptional programs through epigenetic rewiring of upstream regulatory elements. Loss of S100A9 disrupts myeloid differentiation, impairs NK cell maturation, and alters key developmental regulators including CEBPB, JUN, and NFIL3. In vivo, 5-AzaC restores these defects and primes NK cells in a time- and context-dependent manner. Re-analysis of the published Australian MDS/CMML cohort shows that "responders" display increased S100A8/A9 expression together with enhanced IFN-{gamma}, IL6-JAK-STAT3, and TNF signaling. These findings suggest that inflammatory myeloid programs may serve as predictive biomarkers and therapeutic targets to enhance NK cell-mediated graft-versus-leukemia activity posttransplant. SummaryO_LIWe provide compelling evidence that inherent properties of healthy donor CD34+ hematopoietic stem cells (SCs) exist that are likely to contribute to the "response" seen upon pre-emptive posttransplant 5-AzaC therapy of patients with high-risk myelodysplastic syndrome (MDS). C_LIO_LIThese properties are linked to a distinct form of epigenetic plasticity at upstream-located transcription factor (TF) binding sites. This may indirectly contribute to acute S100A8/A9-driven inflammation, which is demonstrable in distinct monocyte subsets and, importantly, also in NK cells thereby determining the characteristics of inflammatory monocyte-NK cell crosstalk. C_LIO_LIMice with a targeted deletion of S100A9 fail to upregulate CEBPB / JUN and NFIL3 which results in impaired myeloid priming and dysfunctional NK cell maturation, respectively. C_LIO_LIRe-analysis of the Australian MDS/CMML cohort confirms that MDS patients that "respond" to 5-AzaC exhibit activated IFN-{gamma}, IL6-JAK-STAT3, and TNF-signaling pathways in the context of upregulated S100A8/A9 after six months of treatment. C_LIO_LIOur study indicates that screening of healthy donors SCs for specific inflammatory markers in early developing monocytes could be used as a marker to predict which donor will have the potential of generating a S100A8/A9-driven inflammatory response. This may help identify patients with MDS as well as AML who are likely to benefit from low-dose, short-term 5-AzaC therapy as early as day 7 after transplantation, potentially resulting in increased graft-versus-leukemia (GvL) activity. C_LI

immunology↗

The systemic JIA synovial fluid environment supports development and prevalence of specific inflammatory T helper cell phenotypes

ObjectiveThe potential involvement of adaptive immunity in systemic juvenile idiopathic arthritis (sJIA) pathophysiology remains an intriguing question. Here, we investigated whether and how the inflammatory environment in sJIA versus JIA synovial fluid (SF) may differentially impact T helper (Th) cell polarization and activation. MethodsSF samples from sJIA and JIA patients (both n=7) were tested in various cell culture setups, with or without recombinant cytokines or cytokine-blocking drugs, to assess their effects on healthy donor Th cell activation. We analyzed cellular surface marker, transcription factor, and effector molecule expression using flow cytometry, Luminex, ELISA, and qRT-PCR. ResultsBoth sJIA and JIA SF revealed highly pro-inflammatory profiles. Compared to JIA, sJIA SF demonstrated markedly elevated IL-1{beta}, IL-18, GM-CSF, S100A9, and MPO levels, while JIA SF showed trends toward higher soluble FasL and IL-17A concentrations. Notably, sJIA SF significantly increased CD4 T cell ICOS expression and expanded CXCR3posCCR6pos Th cells, whereas JIA SF favored expansion of CXCR3negCCR6pos Th cells and CCR6pos Th cell expansion was sensitive to IL-1 blockade. Systemic JIA SF selectively sustained a IFN{gamma}/IL-21 expressing T peripheral helper (Tph) phenotype, particularly associated with IL-1{beta}, IL-18, and GM-CSF SF levels. Spiking JIA SF with a cocktail of these cytokines recapitulated some T cellular phenotypic features observed in sJIA SF cultures. ConclusionJIA and sJIA SF drive distinct Th cell polarization, including differential and sustained Tf/ph cell activation. These findings complement our earlier observations in sJIA peripheral blood and demonstrate the impact of the SF inflammatory matrix on immune cell activation. What is already known on this topicO_LISystemic juvenile idiopathic arthritis (sJIA, Stills Disease) is initially hallmarked by innate immunity driving systemic inflammation C_LIO_LIWith further disease course sJIA can progress to chronic destructive arthritis with several studies suggesting an involvement of adaptive immunity in this process. C_LIO_LIIn a previous study we linked T follicular/peripheral helper (Tfh/Tph) cells in sJIA patients blood to arthritis and self-reactive antibody signatures in patients with longer disease duration C_LI What this study addsO_LIOur study demonstrates that sJIA versus JIA synovial fluid (SF) can drive differential T helper cell (Th cell) polarization and activation. C_LIO_LIOur data imply that sJIA SF promotes the self-sustenance of Th cells with a Tph phenotype characterized by IFN{gamma}, IL-21 and c-MAF expression. C_LIO_LIIL-1{beta}, IL-18, and GM-CSF levels in sJIA SF can be associated with Tph perseverance, and recapitulate sJIA Tph features when spiked into JIA SF. C_LI How this study might affect research, practice or policyO_LIThe present data complement our earlier observations from sJIA peripheral blood and strengthen the biphasic model hypothesis regarding sJIA progression C_LIO_LIWhile both JIA and sJIA patients can develop clinically similar arthritis, our data demonstrate how the respective local inflammatory environments can differentially impact and shape T cell immunity. C_LIO_LIOur data suggest a combined and early targeting of both IL-1{beta} and IL-18 in sJIA may be effective in preventing the generation of inflammatory T cell subsets with the potential to drive chronic arthritis through a joint-localized, adaptive immune response. C_LI

immunology↗

Treatment with 2-phospho-L-ascorbic acid mitigates biochemical phenotypes of heme oxygenase 1 deficiency

Heme oxygenase 1 (HO-1) deficiency is a fatal genetic disorder characterized by impaired heme catabolism, leading to excessive oxidative damage and cell death. Despite evidence from non-human models suggesting mitochondrial dysfunction, the precise pathomechanisms in humans remain unclear, resulting in a lack of effective treatments. Using patient-derived lymphoblastoid cells and HO-1 knockout HEK293T cell models, we demonstrate that HO-1 deficiency is associated with altered mitochondrial morphology and impaired mitochondrial function. Furthermore, it is linked to significant ascorbic acid depletion, accompanied by compensatory upregulation of SVCT2, a key ascorbic acid transporter. Treatment with 2-phospho-L-ascorbic acid, a stable vitamin C analog, restores intracellular ascorbic acid levels and protects cells from hemin-induced cytotoxicity, highlighting its potential as a novel therapeutic strategy for HO-1 deficiency. Our study underscores the critical role of oxidative stress and mitochondrial dysfunction in HO-1 deficiency, paving the way for targeted interventions in this devastating disorder.

molecular biology↗